Physician profile
James Spradlin
NPI 1609828979
$3,387.23
in general payments reported to CMS, 2019-2025
36 companies · $624 in 2025
The $624 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $573 · 2021: $467 · 2022: $485 · 2023: $667 · 2024: $371 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $455.04 | 2019-2023 | Nucala, Shingrix |
| Merck Sharp & Dohme LLC | $404.77 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $234.31 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $233.64 | 2020-2025 | Jardiance, Lyumjev, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $208.29 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $192.57 | 2020-2025 | Airsupra |
| Abbvie INC. | $162.49 | 2021-2025 | Linzess, Viberzi, Vraylar |
| Exact Sciences Corporation | $140.26 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $125.46 | 2019-2025 | |
| Amgen INC. | $115.95 | 2020-2024 | Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $112.28 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.97 | 2023-2025 | Xifaxan, Cycloset, Trulance |
| Otsuka America Pharmaceutical, INC. | $88.13 | 2023-2024 | Rexulti |
| Allergan, INC. | $87.43 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $67.14 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $61.78 | 2025 | Sunosi, Auvelity |
| Abbott Laboratories | $57.91 | 2022-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $56.53 | 2020-2023 | |
| Nestle Healthcare Nutrition INC. | $54.17 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.80 | 2022 | |
| Janssen Pharmaceuticals, INC | $38.40 | 2021-2025 | Spravato |
| Eisai INC. | $37.44 | 2021 | |
| Dexcom, INC. | $36.03 | 2022 | |
| Phathom Pharmaceuticals, INC. | $31.81 | 2025 | Voquezna |
| Harmony Biosciences LLC | $30.64 | 2020 | |
| Ibsa Pharma INC. | $26.76 | 2021-2024 | Tirosint, Licart |
| Seqirus USA INC | $26.43 | 2025 | Flucelvax |
| Inari Medical, INC. | $21.78 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Orexo US, INC. | $18.96 | 2019 | |
| Amarin Pharma, INC. | $18.68 | 2020 | |
| Corcept Therapeutics | $17.22 | 2025 | Korlym |
| Sequel Med Tech, LLC | $17.00 | 2025 | Twiist |
| Averitas Pharma INC. | $15.73 | 2024 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $15.20 | 2021 | |
| Linus Health, INC. | $14.16 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Spradlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.